Clinical Trial

A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized, open-label, multicenter Phase II clinical trial evaluating the efficacy and safety of HB1801 compared with Taxotere® in patients with advanced breast cancer. A total of 60 subjects with advanced breast cancer are planned to be enrolled.The trial consists of three phases: screening period, open-label treatment period, and follow-up period. HB1801 is Docetaxel for injection (Albumin-bound).
Trial Details
NCT Number NCT07083505
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions Advanced Breast Cancer
Enrollment 60 participants
Start Date 2025-08-15
Primary Completion 2026-10-11 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-24